Prediction of breast cancer metastasis by genomic profiling: Where do we stand?

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Current concepts conceive "breast cancer" as a complex disease that comprises several very different types of neoplasms. Nonetheless, breast cancer treatment has considerably improved through early diagnosis, adjuvant chemotherapy, and endocrine treatments. The limited prognostic power of classical classifiers determines considerable over-treatment of women who either do not benefit from, or do not at all need, chemotherapy. Several gene expression based molecular classifiers (signatures) have been developed for a more reliable prognostication. Gene expression profiling identifies profound differences in breast cancers, most probably as a consequence of different cellular origin and different driving mutations and can therefore distinguish the intrinsic propensity to metastasize. Existing signatures have been shown to be useful for treatment decisions, although they have been developed using relatively small sample numbers. Major improvements are expected from the use of large datasets, subtype specific signatures and from the re-introduction of functional information. We show that molecular signatures encounter clear limitations given by the intrinsic probabilistic nature of breast cancer metastasis. Already today, signatures are, however, useful for clinical decisions in specific cases, in particular if the personal inclination of the patient towards different treatment strategies is taken into account.

Original languageEnglish
Pages (from-to)547-558
Number of pages12
JournalClinical & Experimental Metastasis
Volume26
Issue number6
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Therapeutics
Gene Expression Profiling
Adjuvant Chemotherapy
Early Diagnosis
Gene Expression
Drug Therapy
Mutation
Neoplasms

Keywords

  • Angiogenesis
  • Breast cancer
  • Gene expression profiling
  • Metastasis
  • Stroma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prediction of breast cancer metastasis by genomic profiling : Where do we stand? / Pfeffer, Ulrich; Romeo, Francesco; Noonan, Douglas M.; Albini, Adriana.

In: Clinical & Experimental Metastasis, Vol. 26, No. 6, 08.2009, p. 547-558.

Research output: Contribution to journalArticle

@article{abdbae01f2c44560bce1a970235f69b4,
title = "Prediction of breast cancer metastasis by genomic profiling: Where do we stand?",
abstract = "Current concepts conceive {"}breast cancer{"} as a complex disease that comprises several very different types of neoplasms. Nonetheless, breast cancer treatment has considerably improved through early diagnosis, adjuvant chemotherapy, and endocrine treatments. The limited prognostic power of classical classifiers determines considerable over-treatment of women who either do not benefit from, or do not at all need, chemotherapy. Several gene expression based molecular classifiers (signatures) have been developed for a more reliable prognostication. Gene expression profiling identifies profound differences in breast cancers, most probably as a consequence of different cellular origin and different driving mutations and can therefore distinguish the intrinsic propensity to metastasize. Existing signatures have been shown to be useful for treatment decisions, although they have been developed using relatively small sample numbers. Major improvements are expected from the use of large datasets, subtype specific signatures and from the re-introduction of functional information. We show that molecular signatures encounter clear limitations given by the intrinsic probabilistic nature of breast cancer metastasis. Already today, signatures are, however, useful for clinical decisions in specific cases, in particular if the personal inclination of the patient towards different treatment strategies is taken into account.",
keywords = "Angiogenesis, Breast cancer, Gene expression profiling, Metastasis, Stroma",
author = "Ulrich Pfeffer and Francesco Romeo and Noonan, {Douglas M.} and Adriana Albini",
year = "2009",
month = "8",
doi = "10.1007/s10585-009-9254-y",
language = "English",
volume = "26",
pages = "547--558",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Prediction of breast cancer metastasis by genomic profiling

T2 - Where do we stand?

AU - Pfeffer, Ulrich

AU - Romeo, Francesco

AU - Noonan, Douglas M.

AU - Albini, Adriana

PY - 2009/8

Y1 - 2009/8

N2 - Current concepts conceive "breast cancer" as a complex disease that comprises several very different types of neoplasms. Nonetheless, breast cancer treatment has considerably improved through early diagnosis, adjuvant chemotherapy, and endocrine treatments. The limited prognostic power of classical classifiers determines considerable over-treatment of women who either do not benefit from, or do not at all need, chemotherapy. Several gene expression based molecular classifiers (signatures) have been developed for a more reliable prognostication. Gene expression profiling identifies profound differences in breast cancers, most probably as a consequence of different cellular origin and different driving mutations and can therefore distinguish the intrinsic propensity to metastasize. Existing signatures have been shown to be useful for treatment decisions, although they have been developed using relatively small sample numbers. Major improvements are expected from the use of large datasets, subtype specific signatures and from the re-introduction of functional information. We show that molecular signatures encounter clear limitations given by the intrinsic probabilistic nature of breast cancer metastasis. Already today, signatures are, however, useful for clinical decisions in specific cases, in particular if the personal inclination of the patient towards different treatment strategies is taken into account.

AB - Current concepts conceive "breast cancer" as a complex disease that comprises several very different types of neoplasms. Nonetheless, breast cancer treatment has considerably improved through early diagnosis, adjuvant chemotherapy, and endocrine treatments. The limited prognostic power of classical classifiers determines considerable over-treatment of women who either do not benefit from, or do not at all need, chemotherapy. Several gene expression based molecular classifiers (signatures) have been developed for a more reliable prognostication. Gene expression profiling identifies profound differences in breast cancers, most probably as a consequence of different cellular origin and different driving mutations and can therefore distinguish the intrinsic propensity to metastasize. Existing signatures have been shown to be useful for treatment decisions, although they have been developed using relatively small sample numbers. Major improvements are expected from the use of large datasets, subtype specific signatures and from the re-introduction of functional information. We show that molecular signatures encounter clear limitations given by the intrinsic probabilistic nature of breast cancer metastasis. Already today, signatures are, however, useful for clinical decisions in specific cases, in particular if the personal inclination of the patient towards different treatment strategies is taken into account.

KW - Angiogenesis

KW - Breast cancer

KW - Gene expression profiling

KW - Metastasis

KW - Stroma

UR - http://www.scopus.com/inward/record.url?scp=68049120432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049120432&partnerID=8YFLogxK

U2 - 10.1007/s10585-009-9254-y

DO - 10.1007/s10585-009-9254-y

M3 - Article

C2 - 19308665

AN - SCOPUS:68049120432

VL - 26

SP - 547

EP - 558

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 6

ER -